SETUP

EW broke above $92.15 on a gap-up session, clearing a key near-term resistance level with the stock up 2.83% on the day. Price is now trading within striking distance of its 52-week high at $96.29, suggesting a potential challenge of that ceiling. Volume came in at 1.34x average — not explosive, but sufficient to confirm the move. The R/R of 1:1.86 is acceptable, though the signal quality score of 50/100 flags this as a technically stretched entry rather than an early-in-move setup. TP1 at $95.28 and TP2 at $97.30 both sit near the 52-week high zone, meaning resistance will be a real factor.

CATALYSTS

EW has beaten estimates in five consecutive quarters, with the most recent April beat of 7.2% showing earnings momentum is intact. Analyst commentary highlights a differentiated growth runway in structural heart and TAVR markets. Rising competition from Abbott's TriClip study adds pressure on the transcatheter mitral side, but EW's core aortic franchise remains dominant. Options market activity suggests elevated expectations for near-term price movement. Next earnings are not until October 2026, so no binary event risk in the near term.

RISKS

The 52-week high at $96.29 is a major resistance wall sitting just above both targets — price may stall or reverse before TP2 is reached. Signal quality at 50/100 confirms entry is not ideal from a technical positioning standpoint. Insider activity shows heavy sales alongside some purchases, creating a mixed read — the CFO filing of nearly 100,000 shares warrants attention. A P/E of nearly 55x leaves little room for error if growth expectations soften. Broader health care sector or macro risk-off sentiment could cap the move. Stop at $90.64 requires disciplined management given the gap-up open.

CONVICTION: Medium

Five consecutive earnings beats and proximity to the 52-week high support upside potential, but the stretched entry, heavy resistance overhead, and mixed insider signals limit confidence in follow-through to TP2.